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Abstract This paper presents a novel method of multi-drug scheduling using 
multi-objective genetic algorithm (MOGA) that can find suitable/optimum dos-
ages by trading-off between cell killing and toxic side-effects of chemotherapy 
treatment. A close-loop control method, namely Integral-Proportional-Derivative 
(I-PD) is designed to control dosages of drugs to be infused to the patient’s body 
and MOGA is used to find suitable parameters of the controller. A cell compart-
ments model is developed and used to describe the effects of the drugs on different 
type of cells, plasma drug concentration and toxic side-effects. Results show that 
specific drug schedule obtained through the proposed method can reduce the tu-
mour size nearly 100% with relatively lower toxic side-effects.  
1 Introduction 
Cancer refers to a set of malignant disorder where normal cells of the body lose 
their control mechanisms and grow in an uncontrolled way. Cancer cells typically 
proliferate in an exponential fashion and the size of the cancerous mass is meas-
ured experimentally as a volume, though this mass is often referred to in terms of 
the number of cells 4.60517x10
11
 [1]. The main aim of chemotherapy treatment is 
to eradicate or minimise the cancer cells with minimum toxic side-effects. Very 
often, cancer cells grow resistance to Add: drugs that causes failure to treatment in 
most cases. The combination of multiple drugs can decrease the drug resistance. 
Toxic side-effects developed due to the infusion of chemotherapy drugs always 
pose a major challenge in drug scheduling. So drug doses and their cycles of in-
tervals must be designed in such a way that it eradicates the tumour with mini-
mum/tolerable toxic side-effects. The actions of the chemotherapy drugs (agents) 
are based upon an understanding of the cell cycling mechanisms. A number of 
models have been developed to study and analyse the effects of drugs on cancer 
cells by dividing the tumour into number of sub-populations [1-3]. Martin intro-
duced a model for two non-cross resistant agents, which are considered interaction 
between drug concentrations during the treatment within patient body and cells 
2  MOGA-based Multi-drug Optimisation for Cancer Chemotherapy  
 
[2]. Tes et.al. have presented a model to simulate the effects of multi-drug admini-
stration to the cancer cells [1]. Earlier, to explore the potential of classical closed-
loop control strategy, researchers developed two controllers, namely Proportional-
Integral-Derivative (PID) and Integral-Proportional-Derivative (IPD) [4, 5]. The 
controllers were designed to administer a single chemotherapy drug for non-
phase-specific and phase-specific treatments and genetic algorithm (GA) was used 
to optimise the controller parameters by minimising a single design objective; 
mean squared error between the desired drug concentration and actual concentra-
tion. Although the drug scheduling obtained with IPD controller could signifi-
cantly reduce the size of the tumour, other important design objectives such as 
drug resistance and toxic side-effects were ignored in the process [5, 6]. In prac-
tice, multi-drug chemotherapy treatment is preferred to avoid or reduce the risks 
of resistance grown in cancer cells against the infused drug and thus make the 
treatment more effective. In such case, the doses must be optimised to trade off 
between the beneficial and adverse side-effects. Since those are inherently found 
to be in conflict, conventional methods or single objective optimisation techniques 
can hardly provide any suitable solution in multi-drug chemotherapy scheduling 
problem. This paper presents a novel method of multi-drug scheduling using 
Multi-Objective GA (MOGA). Being motivated by the success of IPD controller 
in single drug scheduling problem [6], this research also explores its potential in 
multi-drug scheduling.  
2 Mathematical Model 
For multi-drug chemotherapy treatment, three non-cross resistant drugs are de-
noted by A, B and C, in general, for ease of discussion. A tumour model consists 
of eight compartments are considered as shown in Figure 1 to show the pharma-
cokinetic and pharmacodynamic effects of three drugs in patients’ body during the 
treatment. The sub-population      represents the cells which are sensitive to all 
drugs A, B and C.                      expressed the cells totally resistant to 
drugs A, B and C respectively. The        presents the cells which are doubly re-
sistance for drugs A and B.        and        indicates to cells which are doubly 
resistance for drug A and C, and B and C respectively [2]. The chemotherapy drug 
A is effective on four sub-populations,     ,     ,       and       . While the 
chemotherapy drug B is effective on the four sub-populations,     ,     ,       
and       , on the other hand, the chemotherapy drug C is effective on the four 
sub-populations,     ,     ,       and       . The sub-populations of cancer 
cells that are not resistant to drug A are killed only when the concentration of drug 
A,     is maintained above the drug concentration threshold     . Similarly the 
drug concentration of drug B and C should be raised above the threshold drug 
concentration      and       to kill cells which are not resistant to these drugs. 
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The three sub-populations             increased by the constant rate              which are all less than 1[2]. The total resistance cells for all drugs 
arise from three directions in parallel, as illustrated in Figure 1. 
 
Fig. 1. Eight compartments for multi-drug 
The proportions of cells killed by drug A from the sensitive and resistant sub-
population            are the same, similar to drug B and C [2]. If    indicates 
the rate of growth of cancer cells and   ,    and    are the rate of cancer cells 
killed by drug unit, Equation 1describes the sensitive cell for all drugs, where                              is the Heaviside tep function.                                                                                                                                      
Equation (2) represents the resistance cells for drug A and can be calculated for 
drugs B and C similarly.                                                                                                                                                                                           
Equations 3, 4 and 5 are deriving the cells which are doubly resistance.                                                                                                                                                                                                                     
The initial sizes of the cell sub-populations are:                                                                                                               
The consequence of this model is shown in Equation 7                                                                            
Now the rates of change of drug concentration                      for drugs at 
the tumour site during the treatment cycle are shown, where                       are the amounts of drug doses to be infused to the patient’s 
body and   is the drug decay which is related to the metabolism of drug inside pa-
tient’s body. It should also be noted that all the drug concentrations at the tumour 
site should not exceed the limit of 50 as suggested [2].                                                                            
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Following Equations show the relationship between level of toxicity and drug 
concentration at the tumour site during the treatment. Where                      are the levels of toxicity for all drugs developed inside the patient’s body due to chemotherapy drug and parameter η indicates the rate of 
elimination of toxicity.              η                                                                
Where                      are the level of toxicity for both drugs developed inside the patient’s body due to chemotherapy drug and parameter   indicates the 
rate of elimination of toxicity. Before the treatment starts, the number of cancer 
cells is set at 4.60517x1011, as used by many researchers in cell cycle specific can-
cer treatment [1]. 
3   Implementation 
A schematic diagram of multi-drug scheduling scheme for chemotherapy treat-
ment is shown in Figure 2. A feedback control method I-PD is developed to con-
trol the drug to be infused to the patient’s body. The overall control structure con-
tains three I-PD controllers - one for each drug. Each I-PD controller involves 
three parameters, the proportional gains   , integral gain    and derivative gains   . Drug concentration at the tumour is used as the feedback signal to the control-
ler which is compared with a predefined reference level. The difference between 
each two is called the error which is used as input to the controller. It is notewor-
thy that    ,     and     indicate reference signals to the controllers which can 
be depicted as the desired drug concentrations to be maintained at the tumour site 
during the whole period of treatment. To achieve the desired performance, nine 
parameters of I-PDs such as                                                  
need to be tuned. In this research, MOGA is used to find suitable parameters for I-
PD controllers and reference inputs (desired drug concentrations). 
The mathematical model containing eight compartments stating the effects of 
three drugs as explained earlier is implemented in Matlab/Simulink [8] environ-
ment with parameters and values as illustrated in Table 1 [1]. Moreover, the I-PD 
feedback control scheme is also developed in Matlab/Simulink environment The 
MOGA optimisation process begins with a randomly generated population called 
chromosome. An initial population of dimension 50X12X12 is created where 
number of individuals and parameters in each individual are 50 and 12 respec-
tively. Each parameter is encoded as a 12 bit Gray code which is logarithmically 
mapped [9] into real number within the range of (0, 2) for first nine parameters 
and a range of (10, 50) for the last three parameter. Each individual represents a 
solution where the first nine elements are assigned to controller parameters. The 
last three elements of each individual are assigned to the reference inputs to the 
close-loop control system. The whole control scheme and drug scheduling are de-
signed for a period of 84 days as recommended by many researchers [1, 2, 7,10].  
                                                                                                                                    Algoul et. al. 
 
Fig. 2. Schematic diagram of the proposed multi-drug scheduling scheme  
TABLE I         THE PARAMETERS OF THE SIMULINK MODEL [1] 
parameters Value parameters value parameters value parameters value                   
0.4 day-1 
0.5 day-1 
0.45 day-1 
0.008 
0.01 
0.014 
 
                        
0.32 day 
0.27 day 
0.25 day 
10 D 
10 D 
10 D 
 
                           
 
0 
0 
0 
0 
0 
0 
 
                    
 
0 
0.0084 day-1 D-1 
0.0076 day-1 D-1 
0.0092 day-1 D-1 
0.0099 
4.60517X1011 
At first, MOGA has been used to design drug scheduling which finds the trade-off 
between competing objectives, (i) number of cancer cells at the end of the treat-
ment and (ii) average level of toxicity for three drugs (A, B and C) over the whole 
period of treatment. The four objective functions are formulated as follows:                                                                                                                                                                                                                             are the toxicity for three drugs and    is the total period of 
chemotherapy treatment, i.e., 84 days (12 weeks). The stability of the close-loop 
system and design objectives are used as constraints in the optimisation process in 
order to obtain solutions satisfying all objectives. The constraints are: 
1. Stability of close-loop system 
2. Minimum reduction of cancer cells at the end of treatment:         
3. Maximum level of toxicity during the treatment: 
                            
4. Drug concentration at the tumour site during the treatment: 
                               
After evaluating the fitness function of each individual, as discussed in [11, 12], 
GA operators, namely selection, crossover and mutation are employed on current 
individuals to form individuals of next generation [11, 12]. Selection uses Baker’s 
stochastic universal sampling algorithm [9], which is optimal in terms of bias and 
spread. Solutions not satisfying aforementioned design constraints are penalised 
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with very high values, called penalty function. This penalty function will reduce 
the probability of solutions yielding unacceptable values along any design objec-
tives dominate the optimisation process, and on the contrary, favour acceptable so-
lutions to be selected for reproduction that in turn may generate better solutions in 
subsequent generations. Selected parents are paired up and recombined with high 
probability (0.8). Mating restriction is implemented by forming pairs of individu-
als within a distance of each other in the objective space, where possible. Re-
duced-surrogate shuffle crossover is used for recombination [9]. The mutation rate 
for this optimisation process was set at 0.01%. In MOGA, non-dominated solu-
tions called Pareto optimal set and corresponding decision variables are updated 
and preserved at the end of each generation. The MOGA optimisation process was 
run for 200 generations in order to minimise four design objectives, simultane-
ously and the non-dominated solutions recorded at the end.  
5   Experimental Evaluations 
To obtain different performance measures in relation to treatment, twelve decision 
variables,                                       , and three reference 
inputs (desired drug concentrations), of example solution are fed to the I-PDs con-
trollers and the feedback control system along with the patient model is simulated 
for 84 days (12 weeks). Then the output of the I-PD controller,                      , the desired chemotherapy drug scheduling, are recorded. 
Several outputs of the patient model, such as, drug concentration at tumour site, 
toxicity and reduction of cancer cells are recorded. Figure 4(a) shows the chemo-
therapy drug scheduling for drug (A, B and C). The drug doses increase from zero 
and finally become stable at a certain value. It is noted that the rate of increase is 
different for different three drugs. For drug A, the doses take slightly more than 
one week to reach maximum value of 17.12 and for the remaining periods it be-
comes stable at that same value. Drug B takes less than one week to reach the 
maximum and stable level of 15 and the doses of drug C get stable at the highest 
level which is 12.5 within one week. 
The second graph of Figure 4(b) shows the drug concentration at the tumour site 
due to chemotherapy drug scheduling obtained for all cases earlier in the first 
graph of Figure 4(a). It is interesting to note that, the drug concentrations, for all 
cases, increase gradually in similar manner as observed in case of corresponding 
drug dose scheduling. The drug concentrations at tumour site reach to a maximum 
value as set by the desired values. More importantly, it is noted that, the maximum 
drug concentrations are always much lower than the allowable maximum value 
indicated in design objective and constraint for this particular parameter. 
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Fig. 4. (a) Chemotherapy drug doses for drugs 
A, B and C 
(b) Drug concentration for drugs A, B and C 
Fig. 5. (a) Level of toxicity for drugs A, B and 
C 
(b) The cell reduction throughout the treatment 
period 
The toxicities, for drugs A, B and C, developed due to the corresponding chemo-
therapy drug scheduling are shown in Figure 5(a). For three cases, the toxicities 
gradually increase from the first day of treatment and finally settle to a steady 
value after few days in a similar manner as observed in case of drug scheduling 
and drug concentration. The maximum level of toxicity is observed with the drug 
scheduling obtained with drug A and the value is 92.3 whereas the minimum tox-
icity is caused by drug B is 71.7. Toxicities in all cases remain under control and 
much lower than the maximum limiting value set in design objective and con-
straint of the optimisation process. Figure 5(b) shows the reduction of cancer cells 
during the whole period of treatment. The percentage of reductions obtained using 
the drug scheduling shown in Figure 4(a) is nearly 100% corresponds to the solu-
tion has been chosen. 
6   Conclusion 
The authors investigated and analyzed GA parameters and values that yielded very 
satisfactory results in similar application; the details are described in authors’ ear-
lier works [5, 13]. In this investigation model based on the cells function has been 
used to analyse the effects of the drug scheduling designed by the controller. It is 
noted that the obtained drug schedule is continuous in nature and gives lower and 
stable value throughout the whole period of treatment. Many solutions of the pro-
posed drug scheduling pattern have reduced the number of tumour cells more than 
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99% (eliminate the resistance cells) with the tolerable drug concentration and 
lower toxic side-effects. The proposed model offered better performance as com-
pared to existing models with regard to drug resistance and toxicity level. The 
drug effectiveness (cells reduction) as shown in Figure 5(b) in proposed model is 
nearly 100% while in the existing is about 99%. Where is the maximum level of 
the toxicity 92.3 which produced by drug A in proposed model and 100 for all 
drugs in the existing one [1]. Finally, the same multi-objective optimisation tech-
nique and feedback control strategy can be extended for any higher combination 
regimen. Future work will include verification of the proposed method with clini-
cal data and experiments. 
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